Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.11.2018 | Case report

Nivolumab

Pancreatitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Thompson J, et al. Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS). Journal of Thoracic Oncology 13 (Suppl.): S741 abstr. P2.04-28, No. 10, Oct 2018. Available from: URL: http://doi.org/10.1016/j.jtho.2018.08.1252 [abstract] - USA Thompson J, et al. Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS). Journal of Thoracic Oncology 13 (Suppl.): S741 abstr. P2.04-28, No. 10, Oct 2018. Available from: URL: http://​doi.​org/​10.​1016/​j.​jtho.​2018.​08.​1252 [abstract] - USA
Metadaten
Titel
Nivolumab
Pancreatitis: case report
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-54534-0

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Paracetamol

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Pomalidomide

Case report

Metronidazole